Niagen Bioscience (NAGE) Current Deferred Revenue (2011 - 2026)
Niagen Bioscience (NAGE) posted quarterly Current Deferred Revenue of $380000.0 for Q1 2026, up 83.57% year-over-year from $207000.0 in Q1 2025, and down 4.76% quarter-over-quarter from $399000.0 in Q4 2025.
Powered by 
Analysis
Niagen Bioscience (NAGE) Current Deferred Revenue (2011 - 2026) Analysis & Trends
Niagen Bioscience (NAGE) has reported Current Deferred Revenue for 13 consecutive years, with $380000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Deferred Revenue rose 83.57% year-over-year to $380000.0; the TTM figure through Mar 2026 stood at $380000.0 (up 83.57% YoY), while the FY2025 annual figure was $399000.0, down 34.7% from the prior year.
- Current Deferred Revenue retreated to $380000.0 in Q1 2026 per NAGE's latest filing, from $399000.0 in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $611000.0 in Q4 2024 and bottomed at $141000.0 in Q1 2022.
- Historically, Current Deferred Revenue has averaged $240352.9 across 5 years, with a median of $189000.0 in 2023.
- Annual changes were most pronounced in 2024 — Current Deferred Revenue soared 213.33% — and 2025, when it slumped 34.7%.
- Niagen Bioscience's Current Deferred Revenue stood at $157000.0 in 2022, then rose by 24.2% to $195000.0 in 2023, then jumped by 213.33% to $611000.0 in 2024, then sank by 34.7% to $399000.0 in 2025, then slipped by 4.76% to $380000.0 in 2026.
- Business Quant data shows NAGE's Current Deferred Revenue at $380000.0 in Q1 2026, $399000.0 in Q4 2025, and $292000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Niagen Bioscience | 251.05 Mn | 184.31 Mn | 19.31 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 329,000.00 |
| Mar 31, 2026 | 380,000.00 |
| Dec 31, 2025 | 399,000.00 |
| Sep 30, 2025 | 292,000.00 |
| Jun 30, 2025 | 303,000.00 |
| Mar 31, 2025 | 207,000.00 |
| Dec 31, 2024 | 611,000.00 |
| Sep 30, 2024 | 184,000.00 |
| Jun 30, 2024 | 156,000.00 |
| Mar 31, 2024 | 227,000.00 |
| Dec 31, 2023 | 195,000.00 |
| Sep 30, 2023 | 189,000.00 |
| Jun 30, 2023 | 166,000.00 |
| Mar 31, 2023 | 148,000.00 |
| Dec 31, 2022 | 157,000.00 |
| Sep 30, 2022 | 158,000.00 |
| Jun 30, 2022 | 173,000.00 |
| Mar 31, 2022 | 141,000.00 |
| Dec 31, 2021 | 161,000.00 |
| Sep 30, 2021 | 175,000.00 |